Published online May 28, 2022. doi: 10.3748/wjg.v28.i20.2184
Peer-review started: October 26, 2021
First decision: December 27, 2021
Revised: January 10, 2022
Accepted: April 20, 2022
Article in press: April 20, 2022
Published online: May 28, 2022
Processing time: 213 Days and 4.3 Hours
The critical importance of long noncoding RNAs (lncRNAs) to the onset and exacerbation of colorectal cancer (CRC) has been validated in an increasing number of studies. However, numerous lncRNAs associated with CRC remain unidentified and the detailed mechanisms remain poorly understood. TNFRSF10A-AS1 is a new lncRNA, the function in CRC and gastric cancer is inconsistent and the exact mechanism is unclear.
The present study will clarify the oncogenic pathogenesis of TNFRSF10A-AS1 in CRC progression, leading to new ideas for CRC therapy.
To detect TNFRSF10A-AS1 expression in CRC and investigate the functions and potential mechanisms of TNFRSF10A-AS1 in CRC onset and exacerbation.
In this study, the authors detected TNFRSF10A-AS1 expression in CRC and clarified the relationship between TNFRSF10A-AS1 levels and clinicopathological features of CRC patients. Furthermore, a series of functional experiments both in vitro and in vivo were performed to explore the role of TNFRSF10A-AS1. The mechanism of TNFRSF10A-AS1 mainly focused on its role as a miRNA molecular sponge.
TNFRSF10A-AS1 expression was increased in CRC and positively associated with advanced tumor size and T grade of CRC patients. TNFRSF10A-AS1 enhanced the malignant phenotype of colon cancer cells by promoting CRC proliferation and metastasis. Mechanistically, TNFRSF10A-AS1 was more abundant in the cytoplasm and upregulated the downstream target, HuR, by sponging miR-3121-3p, ultimately promoting CRC progression.
TNFRSF10A-AS1 upregulates HuR expression by sponging miR-3121-3p, ultimately promoting colorectal tumorigenesis and progression. Therefore, TNFRSF10A-AS1 and the TNFRSF10A-AS1/miR-3121-3p/HuR axis may play an important role in CRC onset and exacerbation.
Targeting TNFRSF10A-AS1 and the TNFRSF10A-AS1/miR-3121-3p/HuR axis may have potential novel therapeutic implications for CRC.